Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-838-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.66 million
Profitability
Miscellaneous
Employees121
OptionableOptionable
Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions
What is Aptevo Therapeutics' stock symbol?
Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
How were Aptevo Therapeutics' earnings last quarter?
Aptevo Therapeutics Inc (NASDAQ:APVO) posted its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. The biotechnology company earned $5.82 million during the quarter, compared to analysts' expectations of $6.87 million. Aptevo Therapeutics had a negative return on equity of 78.85% and a negative net margin of 252.44%. View Aptevo Therapeutics' Earnings History.
When is Aptevo Therapeutics' next earnings date?
What price target have analysts set for APVO?
3 brokers have issued twelve-month price targets for Aptevo Therapeutics' shares. Their predictions range from $11.00 to $14.00. On average, they anticipate Aptevo Therapeutics' share price to reach $12.3333 in the next year. This suggests a possible upside of 666.0% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.
What is the consensus analysts' recommendation for Aptevo Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.
Has Aptevo Therapeutics been receiving favorable news coverage?
News stories about APVO stock have been trending positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of Aptevo Therapeutics' key competitors?
Some companies that are related to Aptevo Therapeutics include REDHILL BIOPHAR/S (RDHL), Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Spero Therapeutics (SPRO), Chimerix (CMRX), Adamis Pharmaceuticals (ADMP), Galmed Pharmaceuticals (GLMD), Imprimis Pharmaceuticals (IMMY), OASMIA PHARMACE/ADR (OASM), Marinus Pharmaceuticals (MRNS), Menlo Therapeutics (MNLO), Unum Therapeutics (UMRX) and Processa Pharmaceuticals (PCSA).
Who are Aptevo Therapeutics' key executives?
Aptevo Therapeutics' management team includes the folowing people:
- Mr. Marvin L. White, Pres, CEO & Director (Age 57)
- Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
- Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
- Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
- Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)
How do I buy shares of Aptevo Therapeutics?
Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptevo Therapeutics' stock price today?
One share of APVO stock can currently be purchased for approximately $1.61.
How big of a company is Aptevo Therapeutics?
Aptevo Therapeutics has a market capitalization of $36.72 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.
What is Aptevo Therapeutics' official website?
How can I contact Aptevo Therapeutics?
Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]
MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
